Connect your AI

UroGen Pharma URGN Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

ImmunomeIMNM

$150K+30.4%

Krystal Biotech, Inc.KRYS

$204K-8.9%

TG TherapeuticsTGTX

$573K+26.5%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's non-cash lease expense?: UroGen Pharma (URGN) reported non-cash lease expense of $577K in Q1 2026.
How has UroGen Pharma's non-cash lease expense changed year-over-year?: UroGen Pharma's non-cash lease expense increased by 35.8% year-over-year, from $425K to $577K.
What is the long-term trend for UroGen Pharma's non-cash lease expense?: Over 4 years (2021 to 2025), UroGen Pharma's non-cash lease expense has grown at a 22.2% compound annual growth rate (CAGR), from $942K to $2.1M.
What does non-cash lease expense mean?: Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.